Study Of Serum Anti-Mülierian Hormone Level After Laparoscopic Cystectomy Of Bilateral Benign Ovarian Tumor

Benign ovarian tumor, a kind of commonly encountered disease of female, could beoccured in any age grades, including reproductive women. There has been a generalconsensus that operative laparoscopic cystectomy should be considered the first-linetreatment in benign ovarian tumor, such as symptomatic endometrioma, mature teratoma,and serous cystadenoma. Anti-müllerian hormone(AMH) is expected to become a newmaker for assessment of ovarian function. Studies have shown that serum AMH level canactually reflect the female endocrine status in reproductive age better than conventionalovarian testing, such as follicle stimulating hormone(FSH), estradiol(E2) or luteinizinghormone(LH). We measured serum AMH levels of woman with bilateral benign ovariantumor throughout reproductive age. All patients had undergone laparoscopic ovariancystectomy. Serum AMH levels were serially measured: preoperative,3days and1monthafter operation.[Objective]This study by investigate the serum AMH levels of woman with bilateral benign ovariantumor throughout reproductive age. All patients had undergone laparoscopic ovariancystectomy. Serum AMH levels were serially measured: preoperative,3days and1monthafter operation.[Methods]A total of30woman with bilateral benign ovarian tumor participated in this study. Wedivided the objects into two groups according to pathologic type, endometrioma group andnonendometrioma group. Blood samples were measured by AMH ELISA. On this basis,we divide the objects into different groups according to age and each sampling point(preoperative, postoperative3days and1month). All data input statistical software foranalysis.[Results]1. Serum AMH level of30woman with bilateral benign ovarian tumor is1.99±0.73ng/ml. Linear correlation analysis shows that the AMH levels were negative correlated to age(R=－0.589，P＜0.001)．Serum AMH level is as high as2.64±0.48ng/ml between20to25year-old female，then decline with increasing age，and drop to1.44±0.73ng/mlbetween40to47year-old female.2. Serum AMH levels of woman with bilateral benign ovarian tumor is correlated withpathologic type of tumor. Mean serum AMH level of nonendometrioma group is2.61±0.54ng/ml, and endometrioma group is1.79±0.68ng/ml. There are statisticallysignificantly in each group.3. Serum AMH levels of30patients after3days postoperatively decreased to23.62%ofpreoperative AMH level, and then recovered to34.67%after1month postoperative.According to the pathologic type of the cyst, serum AMH level was found to havedecreased more at3days postoperative in endometrioma compared with nonendometrioticcyst (15.64%vs.41.76%of preoperative AMH level), and recovered less at1monthpostoperative in endometrioma compared with non-endometriotic cyst (25.70%vs.55.56%of preoperative AMH level).[Conclusion]1. AMH is a marker for evaluating ovarian function.2. Serum AMH level of woman with bilateral benign ovarian tumor decline with age.The clinical application of AMH need consideration of the age.3. Serum AMH level of woman with benign ovarian tumor is correlated with pathologictype of tumor. Serum AMH level of the endometrioma patient is statistically significantlylower than the patient of other pathologic type, such as mature teratoma, and serouscystadenoma.4. Serum AMH level decline first, and then increase after laparoscopic cystectomy.Ovarian reserve could be reduced after laparoscopic cystectomy, however, it could berestored postoperative in reproductive women.